Mass Spectrometry Histochemistry of Human FFPE Material Getting Ready for the Clinic Peter Verhaert (1); Kenneth Verheggen (1); Nivedita Bhattacharya (1); Remco Crefcoeur (1); Samruddhi Chawan (1,2), Yury Tsybin (3); Konstantin Nagornov (3); Gilles Frache (4); Cecilia Lindskog-Bergström (5); Emma Lundberg (5); Per Andrén (6); Marthe Verhaert (1,2,7); Sandrine Aspeslagh (2); Raf Sciot (7); Kris Van Der Steen (8); Lin Zhang (9); Ling Shan (9); Dick Swaab (9); Wim Develter (10); Marc Ramael (10) (1) ProteoFormiX, Beerse, Belgium (2) University Hospital, Jette (Brussels), Belgium (3) Spectroswiss, Lausanne, Switzerland (4) Luxembourg Institute of Science and Technology, Esch-sur-Alzette, Luxembourg (5) Human Protein Atlas, Uppsala & Stockholm, Sweden (6) Science for Life Labs, Uppsala Sweden (7) University Hospital, Leuven, Belgium (8) Onze-Lieve-Vrouw Ziekenhuis, Aalst, Belgium (9) The Netherlands Institute for Neuroscience, Amsterdam, the Netherlands (10) Heilig-Hart Ziekenhuis, Lier, Belgium Peter Verhaert, Prof. PhD (Presenter) ProteoFormiX Presenter Bio: Peter VERHAERT was full professor Analytical Biotechnology and Innovative Peptide Biology at Delft University of Technology [Netherlands; 2005 – 2016] before founding his company ProteoFormiX (www.proteoformix.com). His Flemish research startup is alumnus of JLABS, the J&J Innovation Center, and was born at JLABS@BE on the Campus of Janssen Pharmaceuticals in Beerse [Belgium; 2017]. Peter is recognized worldwide as one of the pioneers in Peptidomics, Peptides in Biology being the common theme in his >35 years of research. Prior to taking up his academic position in Delft and ultimately starting his own research company in Beerse, Peter's international career already combined academic and industrial positions: He obtained an MSc in Biology (Zoology Group) and a PhD in Comparative Neurobiology at the University of Leuven, where he held a position as assistant professor [Belgium; 1983-1987]. He then took on a postdoc position at the Laboratory of Toxicology and Biochemistry in the Biology Department of the University of Waterloo [Canada; 1988]. Upon returning to the University of Leuven, he became an associate professor in Histology and Biological Mass Spectrometry [Belgium; 1988-1999]. After an industrial sabbat year at the Flemish Biotech Innogenetics in Ghent [Belgium; 1998-1999], Peter was appointed group leader Proteomics at the Dutch Pharma company Organon (now MSD) in Oss [Netherlands; 2000-2004]. His other professional activities include: • Co-founder and president of the European Pharmaceutical Proteomics Laboratories (EPPL) [2000-2004]; • Proteomics expert at the Flemish Institute of Biotechnology (VIB) [2000-2004]; • Visiting professor Biomedical Proteomics at the Biomedical Research Institute at the Faculty of Medicine of Hasselt University [Belgium; 2004-2014]; • Editor-in-chief of the Elsevier Open Access Journal EuPA Open Proteomics [2013-2016] • Co-director of the Center of Excellence in Biomedical Mass Spectrometry (CEBMMS) at the Faculty of Medicine (Clinical Sciences Department) of Lund University [Sweden; 2016]; • Honorary professor Mass Spectrometry Histochemistry at the Maastricht Multimodal Molecular Imaging Institute (M4i) of Maastricht University [Netherlands; 2017-].